Form 4: Eli Lilly CFO Acquires Over $1.4M in Company Stock

Eli Lilly's Executive Vice President and Chief Financial Officer, Lucas Montarce, acquired 1,365.47 shares of common stock, signaling strong insider confidence.

Summary

• Lucas Montarce, Executive Vice President and Chief Financial Officer of Eli Lilly & Co (LLY), acquired 1,365.47 shares of common stock.
• The transaction occurred on February 9, 2026, at a price of $1,044.67 per share.
• Following this acquisition, Montarce beneficially owns a total of 16,050.206 shares of Eli Lilly common stock.
• The acquisition was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development. A significant acquisition of company stock by the CFO, especially under a 10b5-1 plan, indicates strong confidence in Eli Lilly's future performance and valuation.

Positives

• The acquisition of 1,365.47 shares by a key executive like the CFO demonstrates strong insider confidence in the company's future prospects.
• The transaction value of approximately $1,426,900.00 (1,365.47 shares * $1,044.67/share) represents a significant personal investment by the CFO.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider purchase implicitly suggests a positive outlook from management.

Industry Context

StockSavvy.ai notes that insider buying, especially by a Chief Financial Officer, is often interpreted by the market as a strong signal of management's belief in the company's intrinsic value and future performance, particularly within the competitive pharmaceutical and biotech sectors where R&D pipelines and market approvals are critical drivers.

Stakeholder Impact

• Shareholders may view this as a positive indicator of management's confidence, potentially bolstering investor sentiment.
• Employees may interpret this as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

A seasoned investor would interpret the CFO's substantial acquisition of company stock as a strong vote of confidence in Eli Lilly's future. While not a guarantee of performance, insider buying, particularly by a key financial executive, often precedes positive company developments and suggests that the stock may be undervalued or poised for growth, making it a favorable signal for a 'buy' recommendation.

Keywords

Eli Lilly, LLY, Insider Buying, Form 4, Lucas Montarce, CFO, Stock Acquisition, Pharmaceuticals, Biotech